|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 9/16 | (2006.01) |
| A61K 9/50 | (2006.01) | ||
| A61K 31/5513 | (2006.01) | ||
| A61P 25/22 | (2006.01) | ||
| A61P 25/24 | (2006.01) |
| (11) | Number of the document | 2943185 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14702977.1 |
| Date of filing the European patent application | 2014-01-09 | |
| (97) | Date of publication of the European application | 2015-11-18 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-18 |
| (46) | Date of publication of the claims translation | 2021-03-10 |
| (86) | Number | PCT/US2014/010854 |
| Date | 2014-01-09 |
| (87) | Number | WO 2014/110245 |
| Date | 2014-07-17 |
| (30) | Number | Date | Country code |
| 201361750797 P | 2013-01-09 | US | |
| 201361762833 P | 2013-02-08 | US |
| (72) |
SALTEL, Douglas A., US
VACHON, Michael, US
|
| (73) |
Edgemont Pharmaceuticals, LLC Liquidating Trust,
1037 Raymond Blvd., Suite 1520, Newark, NJ 07102,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Pailginto atpalaidavimo lorazepamo vaisto formos |
| SUSTAINED RELEASE FORMULATIONS OF LORAZEPAM |
| Payment date | Validity (years) | Amount | |
| 2025-11-21 | 13 | 289.00 EUR |
| 2027-01-09 |